Is the Flu Shot Market a Slam Dunk for mRNA Vaccines? Experts Aren’t So Sure
By Helen Branswell Here are two things that are true. The world needs more effective flu vaccines. And pharmaceutical companies that learned of the vaccine-making power of the messenger RNA platform during the COVID-19 pandemic need new markets for their technology. With the heydays of Covid vaccine sales in the rearview mirror, the flu vaccine market, with its antiquated production process that mainly relies on growing viruses in hen’s eggs, seems an obvious candidate for a shake-up. The manufacturers have noticed, with Pfizer, Moderna, GSK, and Sanofi all working on mRNA flu shots. GSK and Sanofi are already major producers The post Is the Flu Shot Market a Slam Dunk for mRNA Vaccines? Experts Aren’t So Sure appeared first on HBCU News.
By Helen Branswell Here are two things that are true. The world needs more effective flu vaccines. And pharmaceutical companies that learned of the vaccine-making power of the messenger RNA platform during the COVID-19 pandemic need new markets for their technology. With the heydays of Covid vaccine sales in the rearview mirror, the flu vaccine market, with its antiquated production process that mainly relies on growing viruses in hen’s eggs, seems an obvious candidate for a shake-up. The manufacturers have noticed, with Pfizer, Moderna, GSK, and Sanofi all working on mRNA flu shots. GSK and Sanofi are already major producers
The post Is the Flu Shot Market a Slam Dunk for mRNA Vaccines? Experts Aren’t So Sure appeared first on HBCU News.
/cloudfront-us-east-1.images.arcpublishing.com/gray/BFMUKWSWURCKTM4CQOY4DVUYOA.jpg)
